{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T12:00:35Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 20.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0957c-6f17-7c03-b0d6-c16cfbeee032\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: periciazine\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 80.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0957c-6f1b-7c30-a19c-ddda6b56ae40\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: periciazine\nRegistry id: vr.tr.periciazine\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:53:40+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:29+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q2622907", "registryId": "vr.tr.periciazine", "name": "periciazine", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q2622907/", "model": { "registry_id": "vr.tr.periciazine", "name": "periciazine", "purpose": "Enable an agent to recognise periciazine, assess the identity and condition of a material sample, and determine which handling or use decisions require further evidence.", "definition": "Periciazine, also called pericyazine or propericiazine, is a synthetic phenothiazine antipsychotic with a piperidine-containing side chain, used medicinally for its dopamine-receptor antagonism.", "scope_statement": "This model owns the substance identity and material-state assessment of periciazine, registry entry vr.tr.periciazine in PHY / PHY.MAT, including its relationship to pharmaceutical ingredients and products.", "in_scope": [ "Molecular identity, verified synonyms and substance identifiers", "Chemical form, composition, purity and batch-specific quality", "Physical properties, stability and storage evidence", "Substance hazards and pharmacological constraints relevant to handling and intended use", "Jurisdiction-specific substance identity and links to authorised medicinal products" ], "out_of_scope": [ "Finished tablet, syrup or other medicinal-product formulations and packaging", "Patient diagnosis, prescribing, dose selection and treatment monitoring", "Manufacturing processes and synthesis-route execution", "Clinical disorders for which a containing product may be prescribed", "Independent models of metabolites, impurities and other phenothiazines" ], "distinguishing_features": [ "Match the molecular structure to a phenothiazine bearing a carbonitrile at position 2 and a 3-(4-hydroxypiperidin-1-yl)propyl substituent at ring nitrogen. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/4747)", "Cross-check the parent substance against CAS 2622-26-6, PubChem CID 4747 and molecular formula C21H23N3OS; formula alone does not establish identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/4747)", "Recognise pericyazine and propericiazine as documented synonyms while retaining the registry's canonical name periciazine. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/4747)", "Require analytical identity evidence to distinguish it from similarly named phenothiazines such as perphenazine; spelling similarity and therapeutic class are insufficient.", "Distinguish the substance from a medicine containing it: a labelled tablet strength describes an ingredient quantity within a formulation. [Pericyazine tablet SmPC](https://www.medicines.org.uk/emc/product/3970/smpc)" ], "characteristics": [ { "name": "Substance identity", "kind": "category", "unit_or_values": "Periciazine; CAS 2622-26-6; PubChem CID 4747", "why_it_matters": "Supports identity reconciliation across suppliers and naming systems. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/4747)" }, { "name": "Molecular composition", "kind": "category", "unit_or_values": "C21H23N3OS for the parent molecule", "why_it_matters": "Provides a composition check when evaluating identity and alternative chemical forms. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/4747)" }, { "name": "Chemical and solid form", "kind": "state", "unit_or_values": "Parent substance or documented alternative form; counterion, solvate, hydrate and solid-form status where established", "why_it_matters": "Prevents transferring mass calculations, properties and specifications between unverified forms." }, { "name": "Assay and reporting basis", "kind": "measurement", "unit_or_values": "% w/w or mg/g; as-is, dried or other explicitly defined basis", "why_it_matters": "Determines how much periciazine a material contains and whether results can be compared." }, { "name": "Related substances and residual materials", "kind": "measurement", "unit_or_values": "%, mg/kg or ppm with analyte, method and reporting limit", "why_it_matters": "Separates parent-substance content from impurities, degradation products, water and residual solvents." }, { "name": "Thermal behaviour", "kind": "measurement", "unit_or_values": "Melting interval or decomposition onset in °C with method; boiling data only where experimentally applicable", "why_it_matters": "Supports material characterisation without treating decomposition as boiling or an estimated value as measured." }, { "name": "Solubility and ionisation conditions", "kind": "measurement", "unit_or_values": "mg/mL or mol/L with solvent, pH and temperature; pKa with method where established", "why_it_matters": "Supports preparation and analytical decisions while preserving the conditions governing the result." }, { "name": "Storage and stability status", "kind": "state", "unit_or_values": "Within supported conditions, excursion under review, failed or unknown; include container and retest date", "why_it_matters": "Determines whether a batch remains suitable for its intended use." }, { "name": "Hazard evidence", "kind": "category", "unit_or_values": "Applicable SDS classifications, jurisdiction, revision date and exposure-control basis", "why_it_matters": "Grounds handling decisions in evidence for the actual material rather than therapeutic classification." }, { "name": "Medicinal-product relationship", "kind": "relation", "unit_or_values": "Linked product, ingredient form, strength basis, jurisdiction and authorisation evidence", "why_it_matters": "Connects the substance to pharmaceutical uses without assigning product approval to every sample." } ], "affordances": [ "Reconcile periciazine and pericyazine records through verified structure and identifiers.", "Compare a batch certificate and analytical results with the specification required for its proposed use.", "Calculate parent-substance content when assay, chemical form and reporting basis are established.", "Select supported storage and handling conditions from material-specific evidence.", "Flag material for further assessment when identity, stability or impurity evidence is inadequate.", "Link containing medicines and their regulatory records while preserving the boundary between substance and product." ], "agent_conduct": { "may": [ "Describe periciazine and its approved uses from medicines information.", "Report the country-specific authorization status, which differs between markets." ], "must_not": [ "Recommend it, a dose or a change of dose for a person.", "Supply it outside the regulated prescription chain.", "Advise stopping it abruptly or combining it with sedatives or alcohol.", "Describe a person as mentally ill because they take it." ], "requires_human": [ "Starting, stopping or changing a person's treatment.", "Use in older people with dementia, where antipsychotics carry raised risk." ] }, "ethics": { "considerations": [ "People treated with antipsychotics face stigma as well as serious side effects.", "Sedating drugs have been misused to control people rather than treat them." ], "affected_parties": [ "Patients and their families", "Carers and prescribers", "Older people in care" ] }, "owners": { "steward": "The marketing authorization holder; medicines regulators and prescribers control its use.", "master_systems": [ "Medicines regulators' product registers" ] }, "visual_identification": [ "Supplied as tablets or oral drops; identified by label, not appearance." ], "failure_modes_and_hazards": [ "Can cause sedation, low blood pressure and movement disorders.", "Raised risk of harm in older people with dementia." ], "what_it_is_for": [ "Periciazine is encountered in pharmaceutical materials and prescription medicines used in psychiatric care.", "It is used for selected psychotic disorders and behavioural disturbances where the particular product is authorised.", "Its identity, formulation and authorised indications matter when assessing a material or medicine containing it." ], "standards_and_regulation": [ "The WHO Collaborating Centre for Drug Statistics Methodology classifies periciazine under ATC code N05AC01 within phenothiazine antipsychotics with a piperidine structure." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q2622907: periciazine", "url": "https://www.wikidata.org/wiki/Q2622907", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Periciazine", "url": "https://en.wikipedia.org/wiki/Periciazine", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "periciazine-identity", "name": "Periciazine identity", "description": "Establish which molecular entity a record or sample represents.", "rationale": "Variant names and similar phenothiazine names can otherwise cause incorrect record merges or substitutions.", "layers": [ { "id": "names-and-identifiers", "name": "Names and identifiers", "description": "Reconcile naming systems with the registered substance.", "findings": [ { "id": "verified-name-equivalence", "name": "Verified name equivalence", "description": "Pericyazine and propericiazine are documented synonyms of periciazine. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/4747)", "questions": [ { "text": "Does this record resolve to periciazine through a matching structure and substance identifier?", "kind": "definition", "id": "verified-name-equivalence-q01" }, { "text": "Which source establishes the equivalence of the supplied name to the registered entry?", "kind": "provenance", "id": "verified-name-equivalence-q02" } ] } ] }, { "id": "structure-and-form", "name": "Structure and form", "description": "Separate molecular identity from the form of the supplied material.", "findings": [ { "id": "parent-versus-supplied-form", "name": "Parent versus supplied form", "description": "A periciazine name match must be supplemented by evidence for the actual chemical form and analytical identity of the material.", "questions": [ { "text": "Does the analytical evidence identify periciazine rather than another phenothiazine or a mixture?", "kind": "measurement", "id": "parent-versus-supplied-form-q01" }, { "text": "Is the sample the parent substance, or does it contain a documented counterion, solvent or water of crystallisation?", "kind": "boundary", "id": "parent-versus-supplied-form-q02" } ] } ] } ] }, { "id": "periciazine-material-quality", "name": "Periciazine material quality", "description": "Assess the amount and quality of periciazine present in a batch.", "rationale": "Research material, reference material and pharmaceutical ingredient require different evidence of suitability.", "layers": [ { "id": "content-and-grade", "name": "Content and grade", "description": "Interpret assay results against the intended use.", "findings": [ { "id": "assay-basis-and-suitability", "name": "Assay basis and suitability", "description": "Record quantitative content with its method and basis; a purity claim alone does not establish pharmaceutical suitability.", "questions": [ { "text": "What is the measured periciazine content, and is it reported as-is, on a dried basis or by another convention?", "kind": "measurement", "id": "assay-basis-and-suitability-q01" }, { "text": "Which specification and supporting records establish suitability for the proposed use?", "kind": "action", "id": "assay-basis-and-suitability-q02" } ] } ] }, { "id": "impurities-and-degradation", "name": "Impurities and degradation", "description": "Evaluate non-parent components without assuming their identities.", "findings": [ { "id": "resolved-impurity-profile", "name": "Resolved impurity profile", "description": "Related substances, unknown peaks and residual materials require separate reporting and applicable acceptance criteria.", "questions": [ { "text": "Which periciazine-related impurities are identified, and what quantities or reporting limits apply?", "kind": "measurement", "id": "resolved-impurity-profile-q01" }, { "text": "Does the analytical method distinguish intact periciazine from degradation products?", "kind": "provenance", "id": "resolved-impurity-profile-q02" } ] } ] } ] }, { "id": "periciazine-physical-state", "name": "Periciazine physical state", "description": "Connect measured properties and stability to the actual material and conditions.", "rationale": "Properties from an unspecified form or finished medicine cannot reliably govern handling of bulk periciazine.", "layers": [ { "id": "conditional-properties", "name": "Conditional properties", "description": "Record thermal and solution behaviour with experimental context.", "findings": [ { "id": "form-specific-property-evidence", "name": "Form-specific property evidence", "description": "Physical constants must identify the tested form, method and conditions, and distinguish measurements from predictions.", "questions": [ { "text": "What measured melting or decomposition interval applies to this periciazine form?", "kind": "measurement", "id": "form-specific-property-evidence-q01" }, { "text": "What solubility is supported at the intended solvent, pH and temperature?", "kind": "measurement", "id": "form-specific-property-evidence-q02" } ] } ] }, { "id": "storage-and-retest", "name": "Storage and retest", "description": "Assess whether the material remains within supported storage and stability limits.", "findings": [ { "id": "substance-specific-stability", "name": "Substance-specific stability", "description": "Bulk-material storage and retest decisions require applicable evidence; finished-product shelf life is not sufficient.", "questions": [ { "text": "Which stability evidence supports the container, temperature and light or moisture controls used for this batch?", "kind": "provenance", "id": "substance-specific-stability-q01" }, { "text": "After a storage excursion or retest-date exceedance, what evidence is required before further use?", "kind": "action", "id": "substance-specific-stability-q02" } ] } ] } ] }, { "id": "periciazine-hazards", "name": "Periciazine hazards", "description": "Separate pharmacological activity from workplace classification and exposure assessment.", "rationale": "An active antipsychotic substance needs handling evidence that cannot be inferred solely from clinical use.", "layers": [ { "id": "pharmacological-constraints", "name": "Pharmacological constraints", "description": "Link relevant biological effects to authoritative medicine information.", "findings": [ { "id": "active-neuroleptic-substance", "name": "Active neuroleptic substance", "description": "Pericyazine is described as a neuroleptic with a powerful central sedative effect; this establishes biological activity, not a workplace exposure limit. [Pericyazine SmPC](https://www.medicines.org.uk/emc/product/3969/smpc)", "questions": [ { "text": "Which documented pharmacological effects are relevant to assessing unintended exposure?", "kind": "definition", "id": "active-neuroleptic-substance-q01" }, { "text": "Which decisions require a linked clinical assessment rather than this substance model?", "kind": "boundary", "id": "active-neuroleptic-substance-q02" } ] } ] }, { "id": "occupational-handling", "name": "Occupational handling", "description": "Determine applicable hazard classifications and exposure controls.", "findings": [ { "id": "material-specific-hazard-assessment", "name": "Material-specific hazard assessment", "description": "Use the applicable safety data sheet and task-specific assessment, preserving uncertainty when exposure limits or classifications are unavailable.", "questions": [ { "text": "Which current SDS and jurisdiction support the hazard classification for this periciazine material?", "kind": "provenance", "id": "material-specific-hazard-assessment-q01" }, { "text": "What containment and protective measures are supported for weighing, transfer or solution preparation?", "kind": "action", "id": "material-specific-hazard-assessment-q02" } ] } ] } ] }, { "id": "periciazine-regulatory-boundaries", "name": "Periciazine regulatory boundaries", "description": "Connect substance identity, intended use and containing products without conflating them.", "rationale": "Substance identification, ingredient quality and medicinal-product authorisation answer different questions.", "layers": [ { "id": "substance-records", "name": "Substance records", "description": "Track applicable identifier and jurisdictional evidence.", "findings": [ { "id": "jurisdictional-identity", "name": "Jurisdictional identity", "description": "Regulatory identifiers and obligations must be associated with the specified substance form, jurisdiction, activity and evidence date.", "questions": [ { "text": "Which authoritative substance records apply to the exact periciazine form being supplied?", "kind": "provenance", "id": "jurisdictional-identity-q01" }, { "text": "What requirements apply to its intended research, manufacture, supply or disposal activity in this jurisdiction?", "kind": "action", "id": "jurisdictional-identity-q02" } ] } ] }, { "id": "containing-medicines", "name": "Containing medicines", "description": "Link pharmaceutical products while retaining their separate ownership of formulation and clinical instructions.", "findings": [ { "id": "ingredient-product-separation", "name": "Ingredient-product separation", "description": "The cited tablet contains 2.5 mg pericyazine alongside excipients; its formulation and clinical instructions belong to the product model. [Pericyazine tablet SmPC](https://www.medicines.org.uk/emc/product/3970/smpc)", "questions": [ { "text": "Which product record identifies periciazine as an ingredient, and how is its strength expressed?", "kind": "boundary", "id": "ingredient-product-separation-q01" }, { "text": "Which current authorisation record supports the product's status in the relevant jurisdiction?", "kind": "provenance", "id": "ingredient-product-separation-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is a recall-based description; no sources were consulted.", "Verify CAS, PubChem and EC identifiers, solid form, purity specifications and physical constants before extending the substance record.", "Check current local product information for authorized uses, contraindications and the complete safety profile; no GHS classification is asserted here." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of periciazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "WHO Anatomical Therapeutic Chemical classification", "value_or_pattern": "N05AC01", "note": "Classified among phenothiazine antipsychotics with a piperidine structure." }, { "scheme": "Molecular formula", "value_or_pattern": "C21H23N3OS", "note": "Describes the neutral parent compound; does not uniquely identify its molecular structure." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of periciazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Active pharmaceutical ingredient in prescription antipsychotic medicines.", "Treatment of schizophrenia and other psychotic disorders where locally authorized.", "Management of certain severe behavioural disturbances under jurisdiction-specific prescribing indications." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of periciazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass of the neutral parent compound", "typical_range": "Approximately 365.49", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of periciazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Sedation and impaired alertness.", "Orthostatic hypotension.", "Anticholinergic effects, including dry mouth, constipation and urinary retention.", "Extrapyramidal movement disorders and tardive dyskinesia.", "Rare but potentially life-threatening neuroleptic malignant syndrome." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of periciazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Names include periciazine, pericyazine and propericiazine.", "Availability, formulations and authorized indications vary by jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of periciazine this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Phenothiazine", "difference": "Phenothiazine is the parent ring system; periciazine is a specific substituted derivative with antipsychotic activity." }, { "name": "Chlorpromazine", "difference": "A distinct phenothiazine antipsychotic with a different ring substituent and an aliphatic rather than piperidine-containing side chain." }, { "name": "Periciazine medicinal product", "difference": "A medicinal product contains the active substance in a specified formulation and strength with excipients; the registered substance is the chemical entity itself." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of periciazine this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative EC identifier, chemical forms and solid forms are established for periciazine, and which apply to available materials?", "Which primary measurements establish melting or decomposition behaviour, solubility and pKa, with form and experimental conditions specified?", "Which current pharmacopoeial monographs or validated specifications define periciazine assay, related substances and acceptance limits?", "Which material-specific SDS classifications, occupational exposure limits or justified exposure-control bands are available?", "What bulk-substance stability studies establish degradation pathways, storage controls and retest periods independently of finished medicinal products?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 27 } }